Expedia Group Inc vs Humana Inc — how do they compare? Expedia Group Inc trades at $274 (market cap $32.42B), while Humana Inc trades at $433 (market cap $46.49B). The key difference: Humana Inc is the larger of the two by market cap, and Humana Inc pays the higher dividend (0.91%). Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and Humana Inc for 51 Days on average.
| EXPE | HUM | |
|---|---|---|
Market Cap | $32.42B | $46.49B |
Volume | 1,940,671 | 2,567,704 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $409.85 |
52-Week Low | $188.51 | $163.67 |
Typical Hold Time | 47 Days | 51 Days |
Enterprise Value | $30.98B | $53.84B |
Dividend Yield | 0.71% | 0.91% |
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $274.22, up 5.93% over the past 24 hours, reflecting strong momentum after three consecutive quarterly earnings beats. The stock shows a bullish technical signal with key resistance at $275 and support at $264. Fundamentally, the company reported $14.73B in 2025 revenue with a net income margin of 12.97%, while recent news highlights AI-driven competitive pressures and strategic partnerships.
The outlook for EXPE is cautiously optimistic, with a consensus price target of $335.06 implying 22% upside. Key opportunities include robust travel demand and improving profitability, but risks involve AI disruption from Meta's Muse agent and heightened competition. Analyst sentiment is mixed, with 47% buy ratings versus 50% hold, signaling balanced but uncertain near-term prospects.
Humana (HUM) trades at $431.03, up 8.71% over the past day, reflecting strong momentum following a Barclays upgrade and positive earnings beats. The stock exhibits a bullish technical trend, with support at $378 and resistance at $394. Revenue has grown steadily from $92.9B in 2022 to $129.7B in 2025, though net income margins have compressed to 0.88%. Analyst consensus is a Buy with a $457.05 price target, and recent news highlights corporate initiatives and institutional investments.
The outlook for HUM is cautiously optimistic, driven by revenue growth and analyst support, but risks include margin pressure and regulatory scrutiny. Investment opportunity lies in execution of Medicare Advantage strategies, while key risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder notices.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →